ICICI Pru Nifty Pharma Index Fund
Ticker: mf13757
Decent
66/100
☆ Add to Watchlist
More Options
K
Kotak International REIT Overseas Equity Omni FOF
The fund shows potential but faces challenges in profitability and valuation. Investors should approach with caution.
View details
I
ICICI Pru Global Stable Equity Fund
The fund shows decent potential with stable growth and profitability metrics, but faces some risks related to governance and execution.
View details
A
Axis Nifty500 Momentum 50 Index Fund
The Axis Nifty500 Momentum 50 Index Fund shows decent potential for growth, but investors should be cautious of market volatility and execution risks.
View details
A
Aditya Birla SL CRISIL IBX Gilt April 2033 Index Fund
The fund offers stability but lacks significant growth potential, making it suitable for conservative investors.
View details
L
LIC MF Healthcare Fund
The LIC MF Healthcare Fund shows potential for growth in a future-ready sector, but faces some valuation and execution risks.
View details
P
PGIM India Corp Bond Fund
The PGIM India Corp Bond Fund shows moderate potential but faces challenges in growth and profitability. Investors should be cautious and consider the risks involved.
View details
M
Mirae Asset Hang Seng TECH ETF FoF
The Mirae Asset Hang Seng TECH ETF FoF presents a decent investment opportunity with exposure to the technology sector, but investors should be cautious of execution risks and valuation metrics.
View details
A
Axis Nifty500 Value 50 Index Fund
The Axis Nifty500 Value 50 Index Fund presents a decent investment opportunity with a balanced approach to value investing, though some risks remain.
View details
L
LIC MF BSE Sensex Index Fund
The LIC MF BSE Sensex Index Fund presents a decent investment opportunity with moderate risks, driven by the overall growth of the index.
View details
D
DSP Nifty SDL Plus G-Sec Sep 2027 50:50 Index Fund
The fund offers a stable investment option with moderate risk, suitable for conservative investors seeking fixed income exposure.
View details
3
360 ONE ELSS Tax Saver Nifty 50 Index Fund
The fund presents a decent investment opportunity with a balanced risk-reward profile, but investors should be cautious of market volatility and execution risks.
View details
J
JioBlackRock Nifty Midcap 150 Index Fund
The JioBlackRock Nifty Midcap 150 Index Fund shows decent potential for growth, but investors should be cautious of execution risks and cash flow consistency.
View details
S
SBI FMP-79-1130D
The stock presents several risks with limited growth potential and inconsistent financial performance.
View details
M
Mirae Asset Nifty AAA PSU Bond Plus SDL Apr 2026 50:50 Index Fund
The fund offers stability and moderate returns but lacks significant growth potential. Suitable for conservative investors seeking fixed income exposure.
View details
E
Edelweiss CRISIL-IBX AAA Bond NBFC-HFC-Jun 2027 Index Fund
The fund shows potential but is hindered by several risks and moderate growth prospects.
View details
I
ICICI Pru Retirement Fund-Hybrid Cons Plan
The fund shows potential for steady growth and profitability, making it a reasonable investment option, though caution is advised due to some execution risks.
View details
Business Overview
The ICICI Pru Nifty Pharma Index Fund is a passive investment option designed to track the performance of the Nifty Pharma Index, which comprises leading pharmaceutical companies in India. This fund is ideal for investors looking to gain exposure to the growing pharmaceutical sector without the need for active management. By investing in this fund, you can benefit from the potential growth of the healthcare industry, driven by increasing demand for medicines and healthcare solutions. It offers diversification, liquidity, and a cost-effective way to invest in a booming sector.
- Tracks Nifty Pharma Index performance
- Ideal for long-term investors
- Exposure to top pharmaceutical companies
- Diversification within the healthcare sector
- Cost-effective passive investment option
Investment Thesis
ICICI Pru Nifty Pharma Index Fund stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuations compared to peers. This fund offers Indian retail investors a solid opportunity to gain exposure to the growing pharmaceutical sector while benefiting from the backing of a reputable financial institution.
- Strong backing from ICICI Group, ensuring credibility and trust.
- Significant growth potential in the digital services segment of the pharma industry.
- Attractive valuation metrics compared to other pharma funds, enhancing investment appeal.
- Diversified exposure to leading pharmaceutical companies in India.
- Aligned with long-term growth trends in healthcare and pharmaceuticals.
Opportunity vs Risk
Opportunities
- Growing healthcare sector in India
- Increased demand for pharmaceuticals
- Government support for healthcare initiatives
- Diversification in investment portfolio
- Long-term growth potential
Risks ⚠️
- Market volatility affecting returns
- Regulatory changes in pharma sector
- Competition from global players
- Economic downturn impacts healthcare spending
- Currency fluctuations affecting imports
Peer Perspective
ICICI Pru Nifty Pharma Index Fund trades at a slight premium compared to peers like Nippon India Pharma and SBI Nifty Pharma. A rerating may occur if the fund achieves consistent margin stability and growth acceleration.
📊 Stock Investment Checklist (100 Points)
ICICI Pru Nifty Pharma Index Fund • Updated: 2025-09-29 13:40:42
-
10BusinessHighPharma sector is future-ready with strong growth potential, but lacks a clear moat.
-
10GrowthHighConsistent revenue growth observed, but profit growth is volatile.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is inconsistent compared to net profit.
-
8ValuationHighP/E and P/B ratios are higher than peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is stable, but some concerns over disclosures.
-
5DriversGoodGrowth catalysts are present, but execution risks remain significant.
-
5TechnicalsGoodMarket sentiment is mixed with low liquidity.
Final Score & Verdict
Score 66 / 100
• Decent
The ICICI Pru Nifty Pharma Index Fund shows decent potential for growth, but investors should be cautious of valuation and execution risks.